Allogeneic hematopoietic stem cell transplantation for therapy-related myeloid neoplasms following treatment of a lymphoid malignancy.

Disease-Free Survival Hematopoietic Stem Cell Transplantation / adverse effects Hodgkin Disease / therapy Humans Neoplasm Recurrence, Local Retrospective Studies Stem Cell Transplantation Transplantation Conditioning Transplantation, Homologous
Clinical results lymphoma and Hodgkin disease myeloid leukemias and dysplasias transplant toxicity

Journal

Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422

Informations de publication

Date de publication:
08 2021
Historique:
pubmed: 30 3 2021
medline: 17 8 2021
entrez: 29 3 2021
Statut: ppublish

Résumé

Advances in lymphoma treatment lead to increasing numbers of long-term survivors. Thus, secondary therapy-related myeloid neoplasms (t-MN) gain clinical relevance. We analyzed 38 t-MN patients receiving an allogeneic stem cell transplantation (SCT) after successful cytotoxic treatment of Hodgkin lymphoma (

Identifiants

DOI: 10.1080/10428194.2021.1894645 PMID: 33779471
pubmed: 33779471
doi: 10.1080/10428194.2021.1894645
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1930-1939

Auteurs

Daniela V Wenge (DV)

Department of Medicine A, Hematology and Oncology, University Hospital Muenster, Muenster, Germany.

Klaus Wethmar (K)

Department of Medicine A, Hematology and Oncology, University Hospital Muenster, Muenster, Germany.

Jan-Henrik Mikesch (JH)

Department of Medicine A, Hematology and Oncology, University Hospital Muenster, Muenster, Germany.

Christian Reicherts (C)

Department of Medicine A, Hematology and Oncology, University Hospital Muenster, Muenster, Germany.

Christoph Schliemann (C)

Department of Medicine A, Hematology and Oncology, University Hospital Muenster, Muenster, Germany.

Rolf Mesters (R)

Department of Medicine A, Hematology and Oncology, University Hospital Muenster, Muenster, Germany.

Torsten Kessler (T)

Department of Medicine A, Hematology and Oncology, University Hospital Muenster, Muenster, Germany.

Cyrus Khandanpour (C)

Department of Medicine A, Hematology and Oncology, University Hospital Muenster, Muenster, Germany.

Andrea Kerkhoff (A)

Department of Medicine A, Hematology and Oncology, University Hospital Muenster, Muenster, Germany.

Norbert Schmitz (N)

Department of Medicine A, Hematology and Oncology, University Hospital Muenster, Muenster, Germany.

Wolfgang E Berdel (WE)

Department of Medicine A, Hematology and Oncology, University Hospital Muenster, Muenster, Germany.

Georg Lenz (G)

Department of Medicine A, Hematology and Oncology, University Hospital Muenster, Muenster, Germany.

Matthias Stelljes (M)

Department of Medicine A, Hematology and Oncology, University Hospital Muenster, Muenster, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Analyse de survie › Survie sans rechute › Allogeneic hematopoietic stem cell...
questionsmedicales.fr › Procédures de chirurgie opératoire › Transplantation › Transplantation cellulaire › Transplantation de cellules souches › Transplantation de cellules souches hématopoïétiques › Allogeneic hematopoietic stem cell...
questionsmedicales.fr › Maladies du système immunitaire › Syndromes immunoprolifératifs › Syndromes lymphoprolifératifs › Lymphomes › Maladie de Hodgkin › Allogeneic hematopoietic stem cell...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Allogeneic hematopoietic stem cell...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Processus néoplasiques › Récidive tumorale locale › Allogeneic hematopoietic stem cell...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › Allogeneic hematopoietic stem cell...
questionsmedicales.fr › Procédures de chirurgie opératoire › Transplantation › Transplantation cellulaire › Transplantation de cellules souches › Allogeneic hematopoietic stem cell...
questionsmedicales.fr › Techniques d'investigation › Techniques immunologiques › Immunosuppression thérapeutique › Conditionnement pour greffe › Allogeneic hematopoietic stem cell...
questionsmedicales.fr › Procédures de chirurgie opératoire › Transplantation › Transplantation homologue › Allogeneic hematopoietic stem cell...